• Emendo raises $61M to build on Takeda-partnered gene editing platform

    13 days ago - By Fierce Biotech

    Emendo Biotherapeutics has raised a $61 million series B to take forward programs based on its gene editing platform. The New York-based biotech has worked to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
    Read more ...